Articles On Orthocell (ASX:OCC)

Regenerative medicine company Orthocell (ASX: OCC) came out of a trading halt this morning with positive interim clinical results for CelGro, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic,...

Australian regenerative medicine company Orthocell (ASX:OCC) has announced positive interim clinical results for the use of its CelGro for enhancing repair of peripheral nerves.

On Stockhead today: five water treatment stocks surge 260 per cent in a year, the ASX’s most intriguing bargain barrel stocks, the five 2019 IPO stocks delivering triple returns and Dorado-3 oil flow gets Carnarvon on track. But first:   Th...

On Stockhead today: the three biggest opportunities for digital transformation in pharma, why it’s time to get excited about cobalt again, the top 10 stocks that doubled (and even tripled) in 24 hours and the stocks investors are shorting r...

In 2019, 10 stocks have gained more than 200 per cent in a single day. Stockhead recaps these stocks, why they gained and where they are now.   10. AssetOwl (ASX: AO1) +225% (16 April) A fellow micro-cap gave AssetOwl a massive leg up back...

The WA investment community will turn its attention to healthcare next Thursday, when the annual Biotech Lunch takes place in Perth. Hosted by industry entrepreneur Brian Leedman, the luncheon will provide a forum for brokers and investors...

Short & Caught is Stockhead’s fortnightly recap of which ASX small cap stocks are heavily shorted. Stocks that are shorted have investors betting that they fall. Shorting works by “selling” stocks you do not actually own in the hope of...

Shares of regenerative medicine company Orthocell Ltd [ASX:OCC] have soared in today’s trading, currently up over 11% at time of writing. The biotech small-cap released the final results today of their CelGro clinical trial, which was succe...

Follow-up results from a CelGro tendon regeneration clinical trial conducted by Perth-based regenerative medicine company Orthocell (ASX: OCC) has confirmed all patients achieved a successful tendon repair with no need for revision surgerie...

04 Sep 2019 - Regenerative medicine company Orthocell (ASX:OCC) reports the final results from patients who completed the CelGro® tendon regeneration clinical trial showing 89 per …

Shares in biotech Orthocell (ASX:OCC) are on the move again today after the company reported further positive results for its CelGro technology. Patients who completed the company’s CelGro tendon regeneration trial reported they had regaine...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Regenerative medicine company Orthocell (ASX:OCC) has announced a Japanese patent for CelGro collagen rope.

The collagen ropes enhance soft tissue repairs to areas such as anterior cruciate ligaments or ACLs.

The healthcare industry of Australia is a key contributor in developing the economy. The companies who are in this industry, have to update them with the new medicine for the treatment of the diseases. The healthcare space of Australia is p...

We’ve been pondering the next recession since the GFC. There have been warning signs, in 2011, 2015, 2016 and the last quarter of last year. But Wednesday’s ‘inverted yield curve’ was the most ominous sign of all, considering every time it...

The pharmaceutical market in Australia is defined as a knowledge-intensive, technology-driven industry that is well poised to contribute to the overall economic activity and particularly enhance social wellbeing. The S&P/ASX 200 Health...

Remember Orthocell (ASX: OCC), that company gained 377 per cent in a day when it showed Cel-Gro helped patients with nerve damage regain sensation? It could be even more powerful than it showed then. While indeed, the trial showed it helpe...

Orthocell (ASX: OCC) published yet another batch of trial results relating to CelGro which it says validates its claim that the technique can deliver higher quality nerve repair compared to existing methods. Earlier this morning, the regene...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. The market opens at 10am (eastern time) and the data is taken at 10:15am, once every stock has commenced trading. Stocks highlighted in yel...

Regenerative medicine company Orthocell (ASX:OCC) has announced positive pre-clinical results for the use of CelGro in enhancing repair of severed peripheral nerves.

When your stock crashes you have three options: run away (and wait to claim the tax loss), sit still and hope things get better or ‘top up’. Speedcast’s (ASX: SDA) Peter Jackson bought $144,000 last week only a few weeks after it crashed. M...

Here’s one that investors can really get their teeth into: Orthocell’s (ASX:OCC) regenerative therapy Celgro quickens and improves dental implant procedures and repairs jangled nerves in more ways than one. To the joy of Collingwood support...

At Stockhead we are as amazed as our readers when stocks rise by over 100 per cent in a day. But its a more common occurrence than we thought. There have been 23 stocks that have achieved that feat. The three most common reasons are success...

The Australian economy, like many countries, is facing challenges in terms of an ageing population, rising chronic diseases, rising demand for new treatments and more hospital beds. S&P/ASX 200 Health Care Index generated an annual retu...

The positive data comes as Orthocell is active in partnering discussions and will support the company to gain traction in key markets.

CV Check Ltd CV Check Ltd (ASX: CV1) is a leading online integrated screening and verification company which offers check products to employers, industry associations and individual customers through the CVCheck brand on its proprietary web...

Orthocell (ASX: OCC) has achieved a substantial reduction in dental implant treatment timeframes during a study using its CelGro regeneration device which facilitates bone and tissue repair and healing. During a single stage dental implant...

Shares in grow-your-own-bone biotech Orthocell (ASX:OCC) are up after it proved, once again, that we live in science fiction times. Today the company said all 10 patients in a dental bone regeneration study had successfully grown enough new...

It’s only a couple of weeks until the end of financial year and some people take steps to minimise their tax. One is selling shares they have made a capital loss on, using them to offset any capital gains. But how can you tell which one are...